



RESPONSE TO COMMENT ON GENUTH

Should Sulfonylureas Remain an Acceptable First-Line Add-on to Metformin Therapy in Patients With Type 2 Diabetes? No, It's Time to Move On! Diabetes Care 2015;38:170–175

Saul Genuth

Diabetes Care 2015;38:e95 | DOI: 10.2337/dc15-0519

I appreciate the attention Schrijnders et al. (1) have given to the Counterpoint article on use of sulfonylureas as an add-on to metformin (2). Several sulfonylureas were compared with regard to the risk of hypoglycemia, but gliclazide was neglected, as it is unfortunately not available in the U.S. Gliclazide was also not mentioned in the Point article by Abrahamson (3), possibly for the same reason. Given the favorable data cited by Schrijnders et al. (4), gliclazide would be a welcome replacement for glyburide in the U.S. market as monotherapy or when appropriate as an add-on to metformin. This is especially so if randomized clinical trial data

ever confirm the cohort study evidence of gliclazide superiority with regard to mortality and cardiovascular events (4,5).

Duality of Interest. No potential conflicts of interest relevant to this article were reported.

References

- Schrijnders D, Houweling ST, Landman GWD. Comment on Genuth. Should sulfonylureas remain an acceptable first-line add-on to metformin therapy in patients with type 2 diabetes? No, it's time to move on! Diabetes Care 2015;38:170–175 (Letter). Diabetes Care 2015;38:e94. DOI: 10.2337/dc15-0293
- Genuth S. Should sulfonylureas remain an acceptable first-line add-on to metformin

therapy in patients with type 2 diabetes? No, it's time to move on! Diabetes Care 2015;38:170–175

- Abrahamson MJ. Should sulfonylureas remain an acceptable first-line add-on to metformin therapy in patients with type 2 diabetes? Yes, they continue to serve us well! Diabetes Care 2015;38:166–169
- Landman GW, de Bock GH, van Hateren KJ, et al. Safety and efficacy of gliclazide as treatment for type 2 diabetes: a systematic review and meta-analysis of randomized trials. PLoS One 2014;9:e82880
- Schramm TK, Gislason GH, Vaag A, et al. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J 2011;32:1900–1908

Case Western Reserve University, Cleveland, OH

Corresponding author: Saul Genuth, smg15@case.edu.

© 2015 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.